Kirstin A Zettlitz1,2, Richard Tavaré3,4, Wen-Ting K Tsai3, Reiko E Yamada5, Noel S Ha3,6, Jeffrey Collins3, R Michael van Dam3,6, John M Timmerman5, Anna M Wu3,7. 1. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA. kzettlitz@coh.org. 2. Department of Molecular Imaging and Therapy, Beckman Research Institute, City of Hope, 1500 E Duarte Rd, Duarte, CA, 91010, USA. kzettlitz@coh.org. 3. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA. 4. Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. 5. Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA. 6. Department of Bioengineering, Samueli School of Engineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA. 7. Department of Molecular Imaging and Therapy, Beckman Research Institute, City of Hope, 1500 E Duarte Rd, Duarte, CA, 91010, USA.
Abstract
PURPOSE: Metabolic imaging using [18F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (18F, t1/2 110 min), enabling same-day imaging. METHODS: GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[18F]-fluorobenzoate ([18F]SFB), or thiol-reactive N-[2-(4-[18F]-fluorobenzamido)ethyl]maleimide ([18F]FBEM) for site-specific conjugation to C-terminal cysteine residues. Both tracers were used for immunoPET imaging of the B cell compartment in human CD20 transgenic mice (hCD20TM). [18F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [18F]FDG PET. Tracer uptake was confirmed by ex vivo biodistribution. RESULTS: The GAcDb was successfully 18F-radiolabeled using two different conjugation methods resulting in similar specific activities and without impairing immunoreactivity. Both tracers ([18F]FB-GAcDb and [18F]FBEM-GAcDb) specifically target human CD20-expressing B cells in transgenic mice. Fast blood clearance results in high contrast PET images as early as 1 h post injection enabling same-day imaging. [18F]FB-GAcDb immunoPET detects disseminated lymphoma disease in the context of normal tissue expression of hCD20, with comparable sensitivity as [18F]FDG PET but with added specificity for the therapeutic target. CONCLUSIONS: [18F]FB-GAcDb and [18F]FBEM-GAcDb could monitor normal B cells and B cell malignancies non-invasively and quantitatively in vivo. In contrast to [18F]FDG PET, immunoPET provides not only information about the extent of disease but also about presence and localisation of the therapeutic target.
PURPOSE: Metabolic imaging using [18F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (18F, t1/2 110 min), enabling same-day imaging. METHODS:GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[18F]-fluorobenzoate ([18F]SFB), or thiol-reactive N-[2-(4-[18F]-fluorobenzamido)ethyl]maleimide ([18F]FBEM) for site-specific conjugation to C-terminal cysteine residues. Both tracers were used for immunoPET imaging of the B cell compartment in humanCD20transgenic mice (hCD20TM). [18F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [18F]FDG PET. Tracer uptake was confirmed by ex vivo biodistribution. RESULTS: The GAcDb was successfully 18F-radiolabeled using two different conjugation methods resulting in similar specific activities and without impairing immunoreactivity. Both tracers ([18F]FB-GAcDb and [18F]FBEM-GAcDb) specifically target humanCD20-expressing B cells in transgenic mice. Fast blood clearance results in high contrast PET images as early as 1 h post injection enabling same-day imaging. [18F]FB-GAcDb immunoPET detects disseminated lymphoma disease in the context of normal tissue expression of hCD20, with comparable sensitivity as [18F]FDG PET but with added specificity for the therapeutic target. CONCLUSIONS:[18F]FB-GAcDb and [18F]FBEM-GAcDb could monitor normal B cells and B cell malignancies non-invasively and quantitatively in vivo. In contrast to [18F]FDG PET, immunoPET provides not only information about the extent of disease but also about presence and localisation of the therapeutic target.
Authors: Kan Liu; Eric J Lepin; Ming-Wei Wang; Feng Guo; Wei-Yu Lin; Yi-Chun Chen; Shannon J Sirk; Sebastian Olma; Michael E Phelps; Xing-Zhong Zhao; Hsian-Rong Tseng; R Michael van Dam; Anna M Wu; Clifton K-F Shen Journal: Mol Imaging Date: 2011-06 Impact factor: 4.488
Authors: Mark Lazari; Serge K Lyashchenko; Eva M Burnazi; Jason S Lewis; R Michael van Dam; Jennifer M Murphy Journal: Appl Radiat Isot Date: 2015-05-21 Impact factor: 1.513
Authors: Adam D Kennedy; Paul V Beum; Michael D Solga; David J DiLillo; Margaret A Lindorfer; Charles E Hess; John J Densmore; Michael E Williams; Ronald P Taylor Journal: J Immunol Date: 2004-03-01 Impact factor: 5.422
Authors: Erik Vegt; Jack F M Wetzels; Frans G M Russel; Rosalinde Masereeuw; Otto C Boerman; Juliette E van Eerd; Frans H M Corstens; Wim J G Oyen Journal: J Nucl Med Date: 2006-03 Impact factor: 10.057
Authors: Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto Journal: J Exp Med Date: 2003-08-18 Impact factor: 14.307
Authors: Lei Kang; Cuicui Li; Zachary T Rosenkrans; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai Journal: J Nucl Med Date: 2020-08-21 Impact factor: 10.057
Authors: Kirstin A Zettlitz; Christopher M Waldmann; Wen-Ting K Tsai; Richard Tavaré; Jeffrey Collins; Jennifer M Murphy; Anna M Wu Journal: J Nucl Med Date: 2019-03-15 Impact factor: 10.057
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Hee-Kwon Kim; Muhammad Rashed Javed; Supin Chen; Kirstin A Zettlitz; Jeffrey Collins; Anna M Wu; Chang-Jin C J Kim; R Michael van Dam; Pei Yuin Keng Journal: RSC Adv Date: 2019-10-09 Impact factor: 4.036